This paper provides some general views on the current guidelines on the purity of medicinal products, with the purpose of informing the medicinal industry about the Danish Medicines Agency's view on how to establish requirements on impurities in chemically-synthesised active substances (the Danish Medicine Agency's rules of thumb do not cover nonchemical substances) and medicinal products for human use. It should be emphasized that the points of views represent the Danish Medicines Agency's interpretation of the quality guidelines in question.
Notice to Applicants. The Rules Governing Medicinal Products in the European Union.Volume 2B. L-2985. Luxembourg: Office for Official Publications of the European Communities; 1998.
2.
Impurities in New Drug Substances (CPMP/ICH/142/95). London, England: Committee for Proprietary Medicinal Products; 1995.
3.
Summary of Requirements for Active Substances in Part II of the Dossier (CPMP/QWP/297/97). London, England: Committee for Proprietary Medicinal Products; 1997.
4.
Technical Guide for the Elaboration of Monographs.3rd Edition. Strasbourg Cedex 1, France: European Directorate for the Quality of Medicines; Internet: www.pheur.org.
5.
Impurities in New Medicinal Products (CPMP/ICH/282/95). London, England: Committee for Proprietary Medicinal Products; 1995.
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (CPMP/ICH/367/96). London, England: Committee for Proprietary Medicinal Products; 1996.
8.
Non Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CPMP/ICH/286/95). London, England: Committee for Proprietary Medicinal Products; 1995.
9.
CramerGMEstimation of toxic hazard—A decision tree approach. Food Cosmetics Toxicol.1978;16:255–276.
10.
MunroICCorrelation of structural class with no-observed-effect levels (NOELs): A proposal for establishing a threshold of concern. Food Cosmetics Toxicol.1996;34:829–867.
